Panacea Life Sciences Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Panacea Life Sciences Holdings generated cash of -$1,524,463, which is more than the previous year. Cash used in financing activities reached the amount of $1,683,756 last year. Net change in cash is therefore $93,971.
Cash Flow
| 2015 | -567.67K | 0 | 598.32K |
|---|---|---|---|
| 2016 | -963.29K | 1.29K | 1.94M |
| 2017 | -1.23M | 0 | 340.8K |
| 2018 | -465.75K | 0 | 306.5K |
| 2019 | -5.74M | -2.04M | 7.80M |
| 2020 | -7.64M | -3.08M | 2.29M |
| 2021 | -3.92M | 522.53K | 3.33M |
| 2022 | -2.39M | -196.97K | 2.58M |
| 2023 | -1.52M | -65.32K | 1.68M |
PLSH Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 6.95K | 19.77K | 84.37K | 8.51M | 1.96K | 161.21K | 1.05M | 72.34K | 41.69K |
Operating activities | |||||||||
Net income | -8.01M | -9.14M | -4.78M | -5.23M | -9.48M | -4.33M | -3.86M | -1.60M | -357.97K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 1.71M | 1.73M | 965.09K | 344.59K | 892.29K | 405.17K | 52.79K | 0 | 1.62K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 3.77M | 0 | 0 | 0 | 5K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 3.77M | 0 | 0 | 0 | 5K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 431.31K | 38.36K | -97.19K | 151.67K | -107.16K | 0 | 0 | 0 | -213 |
Inventories | 297.39K | -184.44K | -547.91K | -5.04M | -2.86M | 0 | 0 | 0 | 0 |
Accounts payable | 1.98M | 1.08M | 1.06M | 684.57K | 973.49K | 188.37K | 210.24K | 491.01K | 84.74K |
Cash generated by operating activities | -1.52M | -2.39M | -3.92M | -7.64M | -5.74M | -465.75K | -1.23M | -963.29K | -567.67K |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 3.08M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -243.80K | -162.94K | -3.20M | -541.20K | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 9.15K | 119.62K | -1.5M | 0 | 0 | 1.29K | 0 |
Cash generated by investing activities | -65.32K | -196.97K | 522.53K | -3.08M | -2.04M | 0 | 0 | 1.29K | 0 |
Financing activities | |||||||||
Common Stock Issued | 0 | 55K | 4.36M | 385K | 7.21M | 50K | 25K | 1.99M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | -904.45K | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 1.44M | 0 | 0 | -50K | 0 |
Repayments of term debt | 0 | 2.58M | -210.55K | -3.96M | 716.05K | -256.5K | 315.8K | 0 | 0 |
Cash used in financing activities | 1.68M | 2.58M | 3.33M | 2.29M | 7.80M | 306.5K | 340.8K | 1.94M | 598.32K |
Net Change In Cash | 93.97K | -12.82K | -64.60K | -8.43M | 16.44K | -159.25K | -894.12K | 982.99K | 30.65K |
Cash at end of period | 100.92K | 6.95K | 19.77K | 84.37K | 18.40K | 1.96K | 161.21K | 1.05M | 72.34K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |